Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $51.7 million.

  • Allogene Therapeutics' Share-based Compensation fell 35.37% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year decrease of 21.66%. This contributed to the annual value of $51.7 million for FY2024, which is 21.54% down from last year.
  • Allogene Therapeutics' Share-based Compensation amounted to $51.7 million in FY2024, which was down 21.54% from $66.0 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Share-based Compensation peaked at $83.6 million during FY2022, and registered a low of $51.7 million during FY2024.
  • For the 3-year period, Allogene Therapeutics' Share-based Compensation averaged around $67.1 million, with its median value being $66.0 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 41.68% in 2020, then fell by 21.54% in 2024.
  • Over the past 5 years, Allogene Therapeutics' Share-based Compensation (Yearly) stood at $65.3 million in 2020, then increased by 23.84% to $80.8 million in 2021, then increased by 3.44% to $83.6 million in 2022, then dropped by 21.11% to $66.0 million in 2023, then dropped by 21.54% to $51.7 million in 2024.